SIA Charts Daily Stock Report (siacharts.com)
The SIA Daily Stock Report utilizes a proven strategy of uncovering outperforming and underperforming stocks from our marquee equity reports; the S&P/TSX 60, S&P/TSX Completion and S&P/TSX Small cap We overlay these powerful reports with our extensive knowledge of point and figure and candlestick chart signals, along with other western-style technical indicators to identity stocks as they breakout or breakdown. In doing so we provide our Elite-Pro Subscribers with truly independent coverage of the Canadian stock market with specific buy and sell trigger points.
Note: Subscribers can screen all Canadian and U.S. stocks and mutual funds, or as components of equally weighted mutual fund sectors indices (e.g. Income Trusts, Precious Metals), and fund groups by issuer (eg. AGF, Dynamic, Franklin Templeton), all Canadian ETFs, ETF Families by issuer (iShares, Horizons, BMO) or as components of Equally Weighted ETF Sector Indices (e.g. 2020+ Target date, Cdn Equity Lg Cap), and create and monitor their own, or SIA's existing model portfolios. Finally, subscribers benefit from being able to generate BUY-WATCH-SELL Signals on demand with SIA Charts proprietary Favoured/Neutral/Unfavoured, SMAX scoring algorithm (see green-yellow-red graph 1 below).
VALEANT PHARMA INTL (VRX.TO) TSX - Mar 19, 2013
GREEN - Favoured / Buy Zone
YELLOW - Neutral / Hold Zone
RED - Unfavoured / Sell / Avoid Zone
VALEANT PHARMA INTL (VRX.TO) TSX - Mar 19, 2013 - Updating from when we last looked at Valeant Pharma (VRX.TO) at the end of January, VRX.TO has broken through resistance at $70 and is moving towards resistance at the $77.28 level. A move above this could see continued strength towards resistance at $85.32. Still found in the #2 position of the SIA S&P'TSX 60 Report, support can be found below at $67.28 and again at $58.57.
***Since entering the Favored zone in Nov of 2011, VRX.TO is up 64% and is up 21.8% in 2013 and up 9% since we last highlighted VRX.TO.
November 9, 2012 - With the announcement of a stock buyback and impressive earnings, in November 2012, Valeant Pharma (VRX.TQ) popped back in to the Favored Zone of the SIA S&P/TSX 60 Report. At the time it was approaching resistance at $46.12, and a break above would see the next potential target at $54.04, which was the prior high from earlier this year. To the downside, support was at $40.95 and again at $35.65, the low from last month (October).
Updating from when we last looked at Valeant Pharma (VRX.TO) at the end of January, VRX.TO has broken through resistance at $70 and is moving towards resistance at the $77.28 level. A move above this could see continued strength towards resistance at $85.32. Still found in the #2 position of the SIA S&P/TSX 60 Report, support can be found below at $67.28 and again at $58.57.
***Since entering the Favored zone in Nov of 2011, VRX.TO is up 64% and is up 21.8% in 2013 and up 9% since we last highlighted VRX.TO.
Important Disclaimer
SIACharts.com specifically represents that it does not give investment advice or advocate the purchase or sale of any security or investment. None of the information contained in this website or document constitutes an offer to sell or the solicitation of an offer to buy any security or other investment or an offer to provide investment services of any kind. Neither SIACharts.com (FundCharts Inc.) nor its third party content providers shall be liable for any errors, inaccuracies or delays in content, or for any actions taken in reliance thereon.
Copyright © siacharts.com
